Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Induction Chemotherapy and Chemoradiotherapy in Nasopharyngeal Cancers (GORTEC-NPC2006)

This study has been terminated.
(Low accrual)
Sponsor:
Information provided by (Responsible Party):
Groupe Oncologie Radiotherapie Tete et Cou
ClinicalTrials.gov Identifier:
NCT00828386
First received: January 22, 2009
Last updated: January 2, 2014
Last verified: January 2014

January 22, 2009
January 2, 2014
January 2009
August 2015   (final data collection date for primary outcome measure)
Event free-survival [ Time Frame: 3 years ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00828386 on ClinicalTrials.gov Archive Site
  • Survival [ Time Frame: 3 years ] [ Designated as safety issue: No ]
  • toxicity [ Time Frame: early and late ] [ Designated as safety issue: Yes ]
  • Cumulative incidence of loco-regional progression [ Time Frame: 3 years ] [ Designated as safety issue: No ]
  • Cumulative rate of metastasis [ Time Frame: 3 years ] [ Designated as safety issue: No ]
  • Global response to chemo-radiotherapy [ Time Frame: 3 years ] [ Designated as safety issue: No ]
  • Global response to induction chemotherapy [ Time Frame: after the induction chemotherapy of the last patient included ] [ Designated as safety issue: No ]
  • Survival [ Time Frame: 3 years ] [ Designated as safety issue: No ]
  • toxicity [ Time Frame: early and late ] [ Designated as safety issue: Yes ]
  • Cumulative incidence of loco-régional progression [ Time Frame: 3 years ] [ Designated as safety issue: No ]
  • Cumulative rate of metastasis [ Time Frame: 3 years ] [ Designated as safety issue: No ]
  • Global response to chemo-radiotherapy [ Time Frame: 3 years ] [ Designated as safety issue: No ]
  • Global response to induction chemotherapy [ Time Frame: after the induction chemotherapy of the last patient included ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Induction Chemotherapy and Chemoradiotherapy in Nasopharyngeal Cancers
A Randomized, Multicenter, Phase III Trial Comparing Induction Chemotherapy With Docetaxel, Cisplatin and 5-Fluorouracil (TPF) Followed by Concurrent Chemoradiotherapy to Concurrent Chemoradiotherapy Alone, in Nasopharyngeal Cancers Staged as T2b, T3, T4 and/or With Lymph Node Involvement (>N1)

This is a randomized, multicenter, phase III trial comparing induction chemotherapy with Docetaxel, Cisplatin and 5-Fluorouracil (TPF) followed by concurrent chemoradiotherapy to concurrent chemoradiotherapy alone, in nasopharyngeal cancers staged as T2b, T3, T4 and/or with lymph node involvement (≥ N1. The main end point is the event free survival.

This is a randomized, multicenter, phase III trial comparing induction chemotherapy with Docetaxel, Cisplatin and 5-Fluorouracil (TPF) followed by concurrent chemoradiotherapy (Arm A) to concurrent chemoradiotherapy alone (Arm B), in nasopharyngeal cancers staged as T2b, T3, T4 and/or with lymph node involvement (≥ N1. The main end point is the event free survival.

The treatments are :

Arm A:

induction chemotherapy: Docetaxel (75 mg/m² administered on D1 of each course, every 3 weeks via one-hour IV infusion) + Cisplatin(75 mg/m² administered on D1 via one-hour infusion )+ 5-FU (750 mg/m²/d administered as a continuous infusion from D1 to D5. The cycles will be repeated every 3 weeks up to a total of 3 courses.

followed by chemoradiotherapy with Cisplatin (40 mg/m2 starting on D1 of the radiation therapy) during 7 weeks

Arm B: Chemoradiotherapy with Cisplatin alone (40 mg/m2 starting on D1 of the radiation therapy) during 7 weeks

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Nasopharyngeal Cancers
Procedure: Induction chemotherapy + concurrent radiochemotherapy vs. concurrent radiochemotherapy
Induction chemotherapy (Docetaxel, Cisplatin and 5-Fluorouracil) + concurrent radiochemotherapy
  • Experimental: Induction chemotherapy + concurrent chemoradiotherapy

    Induction chemotherapy (Docetaxel + Cisplatin + 5-FU):

    • Docetaxel 75 mg/m² administered on D1 of each course, every 3 weeks, via one-hour IV infusion
    • Cisplatin 75 mg/m² administered on D1 via one-hour infusion followed by
    • 5-Fluorouracil (as a continuous infusion): 750 mg/m²/d administered as a continuous infusion from D1 to D5.

    The cycles will be repeated every 3 weeks up to a total of 3 courses. Followed by concurrent chemoradiotherapy with Cisplatin : weekly Cisplatin 40 mg/m2 starting on D1 of the radiation therapy (70 Gy/7 weeks).

    Intervention: Procedure: Induction chemotherapy + concurrent radiochemotherapy vs. concurrent radiochemotherapy
  • Active Comparator: Concurrent radiochemotherapy alone
    Concurrent chemoradiotherapy with Cisplatin : weekly Cisplatin 40 mg/m2 starting on D1 of the radiation therapy (70 Gy/7 weeks).
    Intervention: Procedure: Induction chemotherapy + concurrent radiochemotherapy vs. concurrent radiochemotherapy
Bourhis J, Sire C, Graff P, Grégoire V, Maingon P, Calais G, Gery B, Martin L, Alfonsi M, Desprez P, Pignon T, Bardet E, Rives M, Geoffrois L, Daly-Schveitzer N, Sen S, Tuchais C, Dupuis O, Guerif S, Lapeyre M, Favrel V, Hamoir M, Lusinchi A, Temam S, Pinna A, Tao YG, Blanchard P, Aupérin A. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. Lancet Oncol. 2012 Feb;13(2):145-53. doi: 10.1016/S1470-2045(11)70346-1. Epub 2012 Jan 18.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
83
August 2015
August 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. WHO II-III carcinoma of the nasopharynx, histologically proven by a nasal cavity biopsy, locally advanced T2b, T3, T4 and/or N1, N2 or N3 (UICC/AJCC2002).
  2. Absence of distant metastases, confirmed by a chest CT scan, abdominal ultrasound (or CT scan) in case of abnormal hepatic function, and bone scintigraphy required.
  3. Total absence of previous chemotherapy or radiotherapy, for whatever reason.
  4. Total absence of surgical procedures for nasopharyngeal carcinoma.
  5. Total absence of concurrent cancer treatment.
  6. Total absence of chronic treatment (>= 3 months) with corticosteroids with a daily dosage >= 20 mg/day of methylprednisolone or equivalent.
  7. Age between 18 and 70 years.
  8. Performance status 0 or 1 according to the WHO criteria.
  9. Hematological function parameters performed within 10 days before inclusion:

    • Neutrophils >= 1.5 * 109/l
    • Platelets: >= 100 * 109/l
    • Hemoglobin: >= 10 g/dl
  10. Hepatic function parameters performed within 10 days before inclusion:

    • Total bilirubin is normal
    • AST (SGOT) and ALT (SGPT) <= 2.5 * upper limit of normal (ULN) of each center.
    • Alkaline phosphatase <= 2.5 * ULN.
  11. Renal function parameters performed within 10 days before inclusion: Creatinine clearance must be <= 55 ml/min.
  12. Patient who has given his/her written consent before any specific procedure of the protocol.
  13. Patient having a Social Security (social policy-holders)

Exclusion Criteria:

  1. WHO I carcinoma of the nasopharynx, histologically proven by a nasal cavity biopsy.
  2. Other previous or concomitant cancer, except for in situ cervical cancer and cutaneous basal cell carcinoma.
  3. Histological diagnosis on a lymph node biopsy.
  4. Pregnant or breast-feeding females, or females and males of childbearing potential not taking adequate contraceptive measures.
  5. Symptomatic peripheral neuropathy with grade >= 2 according to the NCI-CTC criteria.
  6. Other serious concurrent medical disease (non-exhaustive list):

    • Unstable heart disease despite treatment.
    • Myocardial infarction within 6 months before inclusion in the trial.
    • A history of neurological or psychiatric events such as dementia, convulsions.
    • Severe uncontrolled infection.
    • Active gastroduodenal ulcer.
    • Obstructive Pulmonary Disease requiring hospitalization within the year prior to inclusion.
  7. Clinical impairment of auditory function.
  8. The presence, at time of screening, of psychological, familial, social or geographical factors that may have an effect on the compliance of the patient with the study protocol and monitoring comprises an exclusion criterion. These factors must be discussed with the patient before his or her inclusion in the trial.
  9. Hypersensitivity to the excipients.
  10. A patient already enrolled in another therapeutic trial on an investigational compound.
  11. A person deprived of liberty or in the care of a guardian.

    -

Both
18 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
France,   Morocco,   Romania,   Tunisia
 
NCT00828386
GORTEC-NPC2006
Not Provided
Groupe Oncologie Radiotherapie Tete et Cou
Groupe Oncologie Radiotherapie Tete et Cou
Not Provided
Principal Investigator: Jamel Daoud, Pr Hôpital Habib Bourguiba-3029 Sfax-Tunisie
Principal Investigator: Mounir FRIKHA, Pr Hôpital Habib Bourguiba-3029 Sfax-Tunisie
Principal Investigator: Jean BOURHIS, Pr Institut Gustave Roussy, 39 rue Camille Desmoulin, Villejuif, France
Groupe Oncologie Radiotherapie Tete et Cou
January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP